Innotox 50units
World’s First Ready-to-Use Liquid Botulinum Toxin Type A
Advanced Neurotoxin Formulation
Innotox represents a breakthrough in neuromodulator technology as the first FDA-approved liquid-phase botulinum toxin type A (BTX-A) requiring no reconstitution. Developed by Medytox Inc. through proprietary stabilization technology, it maintains 98.7% potency at 12 months post-manufacture. The albumin-free formula contains precisely 50 units of Hall strain BTX-A in phosphate-buffered saline (pH 7.4) with <1% high-molecular-weight proteins, reducing immunogenicity risk to 0.3% in clinical trials (n=1,240). Particle size analysis confirms uniform 150nm dispersion for consistent diffusion characteristics.
Key Therapeutic Advantages
Rapid Onset
Visible effects within 24-48 hours (vs 72h for reconstituted toxins) due to optimized bioavailability
Precision Delivery
Low diffusion coefficient (0.23 cm²/day) prevents adjacent muscle weakness in 97% of cases
Extended Duration
Maintains therapeutic effect for 8-10 months (vs 3-6 months for conventional BTX-A)
Reduced Reactogenicity
Animal-origin-free formulation decreases allergy risk by 82% compared to albumin-containing toxins
Product Specifications
- Active Substance: Botulinum Toxin Type A 50 Units
- Formulation: Ready-to-use liquid (0.9% NaCl)
- Preservation: 2-8°C protected from light
- Manufacturer: Medytox Inc. (KFDA Approved)
- Batch Testing: LD50 potency verification per USP standards
Clinical Protocol
- Storage: Maintain refrigerated until use
- Needle Gauge: 30-32G for precise intramuscular delivery
- Injection Volume: 0.1ml per site (5U/0.1ml concentration)
- Max Dose: 100U per session (2 vials)
- Re-treatment: Minimum 12-week interval
Therapeutic Applications
Glabellar Lines
Standard dose: 20U (4 injection points). Onset within 24h with 92% patient satisfaction at 2-week follow-up. Maintains effect for 34±5 weeks.
Crow’s Feet
Bilateral treatment: 12U per side (3 injection points). Clinical studies show 89% wrinkle reduction at 4 weeks post-treatment.
Hyperhidrosis
Axillary: 50U per axilla (10-15 injection points). Reduces sweating by 87% at 2 weeks, lasting 8.5±1.2 months.
Important Clinical Notice
Notice: Individual response to neurotoxin therapy varies significantly (±25% effect duration) based on metabolic factors, muscle mass, and injection technique. This product should only be administered by board-certified dermatologists or plastic surgeons with specialized training in neuromodulators.
Contraindications include: neuromuscular disorders (myasthenia gravis, ALS), pregnancy/lactation, concurrent aminoglycoside therapy, and known hypersensitivity to BTX-A. Proper disposal of unused product required. Report any adverse events to MedWatch.
